From: Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea
Lung cancer subtype | Stage | Total | P value* | |
---|---|---|---|---|
NSCLC | Stage I–II | Stage III–IV | 0.011 | |
2017 (Feb–Jun) | 51 (42.1%) | 70 (57.9%) | 121 | |
2018 (Feb–Jun) | 41 (33.3%) | 82 (66.7%) | 123 | |
2019 (Feb–Jun) | 53 (37.3%) | 89 (62.7% | 142 | |
2020 (Feb–Jun) | 37 (25.3%) | 109 (74.7%) | 146 | |
Total (Feb–Jun) | 182 (34.2%) | 350 (65.8%) | 532 | |
SCLC | Limited disease | Extensive disease | 0.239 | |
2017 (Feb–Jun) | 5 (29.4%) | 12 (70.6%) | 17 | |
2018 (Feb–Jun) | 4 (25%) | 12 (75%) | 16 | |
2019 (Feb–Jun) | 5 (20.8%) | 19 (79.2%) | 24 | |
2020 (Feb–Jun) | 11 (47.8%) | 12 (52.2%) | 23 | |
Total (Feb–Jun) | 25 (31.3%) | 55 (68.8%) | 80 |